LAUREL ZUBERI: Open Payments
NPI 1457395311 · PORTLAND, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,677 in 120 payments from 23 companies in 2025. Trend: 2023 $2,277 · 2024 $2,302 · 2025 $2,677
Food & beverage: $2,677
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 22 | $407 |
| Novo Nordisk Inc | 12 | $305 |
| Xeris Pharmaceuticals, Inc. | 13 | $274 |
| Novartis Pharmaceuticals Corporation | 9 | $241 |
| Tandem Diabetes Care, Inc. | 2 | $158 |
| Abbott Laboratories | 7 | $139 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $131 |
| Medtronic, Inc. | 7 | $118 |
| Neurocrine BioSciences, Inc. | 5 | $115 |
| Alexion Pharmaceuticals, Inc. | 4 | $115 |
Products named: EVENITY, LEQVIO, GVOKE HYPOPEN, Wegovy, t:slim X2 Insulin Pump with Control-IQ, FREESTYLE LIBRE 3, JARDIANCE, MINIMED 780G.
Industry payments across OR — which companies pay providers there.
